Pentostatin and cyclophosphamide with or without rituximab has significant activity in patients with previously treated chronic lymphocytic leukemia and other low grade lymphoid neoplasms.

被引：4

作者：

Lamanna, N

Kalaycio, M

Maslak, P

Jurcic, J

Scheinberg, DA

Gencarelli, AN

Horgan, D

Weiss, MA

机构：

[1] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA

[2] Cleveland Clin Fdn, Cleveland, OH 44195 USA

来源：

BLOOD | 2004年 / 104卷 / 11期

关键词：

D O I：

10.1182/blood.V104.11.3484.3484

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3484

引用

页码：950A / 950A

页数：1

共 50 条

[1] Pentostatin, cyclophosphamide, and rituximab show significant clinical activity in patients with previously untreated chronic lymphocytic leukemia
Nicole Lamanna
Mark A. Weiss
Current Oncology Reports, 2007, 9 (5) : 335 - 336
[2] Combination chemotherapy regimens with pentostatin in patients with chronic lymphocytic leukemia and other low grade lymphoid neoplasms
Weiss, MA
Kalaycio, M
Zelenetz, AD
Lamanna, N
ANNALS OF ONCOLOGY, 2005, 16 : 258 - 258
[3] Pentostatin, cyclophosphamide, and rituximab (PCR) has comparable activity but appears to be better tolerated than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia.
Lamanna, N
Kalaycio, M
Maslak, P
Heaney, ML
Brentjens, R
Jurcic, J
Biederman, E
Gencarelli, AN
Panageas, KS
Scheinberg, DA
Weiss, MA
BLOOD, 2005, 106 (11) : 601A - 602A
[4] Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
Lamanna, N
Kalaycio, M
Maslak, P
Jurcic, JG
Heaney, M
Brentjens, R
Zelenetz, AD
Horgan, D
Gencarelli, A
Panageas, KS
Scheinberg, DA
Weiss, MA
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (10) : 1575 - 1581
[5] Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Kay, Neil E.
Geyer, Susan M.
Call, Timothy G.
Shanafelt, Tait D.
Zent, Clive S.
Jelinek, Diane F.
Tschumper, Renee
Bone, Nancy D.
Dewald, Gordon W.
Lin, Thomas S.
Heerema, Nyla A.
Smith, Lisa
Grever, Michael R.
Byrd, John C.
BLOOD, 2007, 109 (02) : 405 - 411
[6] Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia
Weiss, MA
Maslak, PG
Jurcic, JG
Scheinberg, DA
Aliff, TB
Lamanna, N
Frankel, SR
Kossman, SE
Horgan, D
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) : 1278 - 1284
[7] Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia
Shanafelt, Tait D.
Lin, Thomas
Geyer, Susan M.
Zent, Clive S.
Leung, Nelson
Kabat, Brian
Bowen, Deborah
Grever, Michael R.
Byrd, John C.
Kay, Neil E.
CANCER, 2007, 109 (11) : 2291 - 2298
[8] Pentostatin and cyclophosphamide compared to pentostatin, cyclophosphamide, and rituximab as salvage therapy for patients with chronic lymphocytic leukemia.
Weiss, MA
Lamanna, N
Kalaycio, M
Jurcic, J
Maslak, P
Gencarelli, A
Scheinberg, D
Horgan, D
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 574S - 574S
[9] Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia.
Kay, Neil
Geyer, Susan
Call, Timothy
Shanafelt, Tait
Zent, Clive
Jelinek, Diane
Tschumper, Renee
Bone, Nancy
Dewald, Gordon
Lin, Thomas
Heerema, Nyla
Smith, Laura
Grever, Michael
Byrd, John
BLOOD, 2006, 108 (11) : 15A - 15A
[10] Pentostatin, cyclophosphamide and rituximab is an active regimen with low toxicity for previously treated patients with B-cell chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia
Hensel, M
Krasniqi, F
Villalobos, M
Kornacker, M
Ho, AD
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 571S - 571S

← 1 2 3 4 5 →